Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry.

[1]  J. Butler,et al.  Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction , 2021, Heart Failure Reviews.

[2]  S. Solomon,et al.  Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. , 2020, JAMA cardiology.

[3]  P. Ponikowski,et al.  Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials , 2020, European journal of heart failure.

[4]  J. Butler,et al.  Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event , 2020, Advances in Therapy.

[5]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[6]  P. Ponikowski,et al.  Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial , 2019, European journal of heart failure.

[7]  J. H. Patterson,et al.  Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[8]  Mahesh J. Patel,et al.  Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[9]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[10]  J. H. Patterson,et al.  Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial , 2018, Journal of the American Heart Association.

[11]  P. Ponikowski,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. , 2017, JACC. Heart failure.

[12]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.

[13]  J. Januzzi,et al.  The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. , 2016, JACC. Heart failure.

[14]  S. Solomon,et al.  Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.

[15]  Laura G. Qualls,et al.  In‐Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization , 2014, Journal of the American Heart Association.

[16]  Paul Heidenreich,et al.  Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. , 2013, Journal of the American College of Cardiology.

[17]  J. Messenger,et al.  The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.

[18]  Donna Buchanan,et al.  Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. , 2010, Journal of the American College of Cardiology.

[19]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.